Trial · NCT01715896
Results by group155
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 155
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Golimumab 50 mg Alternating With Placebo | 65.6 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 20 (ACR20) Responses at Day 169 | Mavrilimumab 100 mg | 62.0 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Responses at Day 169 | Golimumab 50 mg Alternating With Placebo | 43.4 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 50 (ACR50) Responses at Day 169 | Mavrilimumab 100 mg | 34.8 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Responses at Day 169 | Golimumab 50 mg Alternating With Placebo | 25.9 | percentage of participants | ||
| Percentage of Participants Who Achieved American College of Rheumatology 70 (ACR70) Responses at Day 169 | Mavrilimumab 100 mg | 16.1 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 169 | Golimumab 50 mg Alternating With Placebo | 29.0 | percentage of participants | ||
| Percentage of Participants Who Achieved Disease Activity Score of 28 Joints Using C-Reactive Protein (DAS28 [CRP]) Response at Day 169 | Mavrilimumab 100 mg | 17.4 | percentage of participants | ||
| Percentage of Participants Who Achieved Health Assessment Questionnaire Disability Index (HAQ-DI) Score Improvement From Baseline and >= 0.25 at Day 169 | Golimumab 50 mg Alternating With Placebo | 69.0 | percentage of participants | ||
| Percentage of Participants Who Achieved Health Assessment Questionnaire Disability Index (HAQ-DI) Score Improvement From Baseline and >= 0.25 at Day 169 | Mavrilimumab 100 mg | 58.7 | percentage of participants | ||
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Golimumab 50 mg Alternating With Placebo | TEAEs | 29 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TEAEs | 36 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Golimumab 50 mg Alternating With Placebo | TESAEs | 3 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | TESAEs | 2 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Golimumab 50 mg Alternating With Placebo | Investigational-product-related TEAE | 11 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | Investigational-product-related TEAE | 12 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Golimumab 50 mg Alternating With Placebo | Severe TEAE | 3 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | Severe TEAE | 1 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Golimumab 50 mg Alternating With Placebo | Acute TEAEs | 7 | participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs) | Mavrilimumab 100 mg | Acute TEAEs | 5 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01715896/results